The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report 2025
Synopsis
The global market for Amyotrophic Lateral Sclerosis (ALS) Treatment was valued at US$ 350 million in the year 2024 and is projected to reach a revised size of US$ 599 million by 2031, growing at a CAGR of 8.1% during the forecast period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global market for Amyotrophic Lateral Sclerosis (ALS) Treatment was valued at US$ 350 million in the year 2024 and is projected to reach a revised size of US$ 599 million by 2031, growing at a CAGR of 8.1% during the forecast period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2020-2031)
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
2.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
2.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
2.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
2.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
2.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
3.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2020-2025)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue
3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio
3.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2024
3.5 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment Head office and Area Served
3.6 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Product and Application
3.7 Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2026-2031)
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
6.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
7.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
9.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
9.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mitsubishi Tanabe Pharma
11.1.1 Mitsubishi Tanabe Pharma Company Details
11.1.2 Mitsubishi Tanabe Pharma Business Overview
11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.1.5 Mitsubishi Tanabe Pharma Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.2.5 Sanofi Recent Development
11.3 Mylan Pharma
11.3.1 Mylan Pharma Company Details
11.3.2 Mylan Pharma Business Overview
11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.3.5 Mylan Pharma Recent Development
11.4 Apotex
11.4.1 Apotex Company Details
11.4.2 Apotex Business Overview
11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.4.5 Apotex Recent Development
11.5 Glemark Generics
11.5.1 Glemark Generics Company Details
11.5.2 Glemark Generics Business Overview
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.5.5 Glemark Generics Recent Development
11.6 Covis Pharma
11.6.1 Covis Pharma Company Details
11.6.2 Covis Pharma Business Overview
11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.6.5 Covis Pharma Recent Development
11.7 Sun Pharma
11.7.1 Sun Pharma Company Details
11.7.2 Sun Pharma Business Overview
11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.7.5 Sun Pharma Recent Development
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Details
11.8.2 Lunan Pharma Business Overview
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
11.8.5 Lunan Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Riluzole
Table 3. Key Players of Edaravone (Radicava)
Table 4. Key Players of Other
Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2020-2025)
Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2026-2031)
Table 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
Table 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
Table 13. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
Table 14. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players (2020-2025)
Table 17. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2024)
Table 18. Ranking of Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Headquarters and Area Served
Table 21. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Product and Application
Table 22. Global Key Players of Amyotrophic Lateral Sclerosis (ALS) Treatment, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2020-2025)
Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2026-2031)
Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2020-2025)
Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2026-2031)
Table 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031) & (US$ Million)
Table 47. Mitsubishi Tanabe Pharma Company Details
Table 48. Mitsubishi Tanabe Pharma Business Overview
Table 49. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 50. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 51. Mitsubishi Tanabe Pharma Recent Development
Table 52. Sanofi Company Details
Table 53. Sanofi Business Overview
Table 54. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 55. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 56. Sanofi Recent Development
Table 57. Mylan Pharma Company Details
Table 58. Mylan Pharma Business Overview
Table 59. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 60. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 61. Mylan Pharma Recent Development
Table 62. Apotex Company Details
Table 63. Apotex Business Overview
Table 64. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 65. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 66. Apotex Recent Development
Table 67. Glemark Generics Company Details
Table 68. Glemark Generics Business Overview
Table 69. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 70. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 71. Glemark Generics Recent Development
Table 72. Covis Pharma Company Details
Table 73. Covis Pharma Business Overview
Table 74. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 75. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 76. Covis Pharma Recent Development
Table 77. Sun Pharma Company Details
Table 78. Sun Pharma Business Overview
Table 79. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 80. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 81. Sun Pharma Recent Development
Table 82. Lunan Pharma Company Details
Table 83. Lunan Pharma Business Overview
Table 84. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
Table 85. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025) & (US$ Million)
Table 86. Lunan Pharma Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
Table 90. Authors List of This Report
List of Figures
Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Picture
Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type: 2024 VS 2031
Figure 4. Riluzole Features
Figure 5. Edaravone (Radicava) Features
Figure 6. Other Features
Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Drugs Store Case Studies
Figure 11. Other Case Studies
Figure 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Report Years Considered
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region: 2024 VS 2031
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players in 2024
Figure 17. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2024
Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
Figure 21. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
Figure 25. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2020-2031)
Figure 33. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
Figure 41. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
Figure 45. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Mitsubishi Tanabe Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 49. Sanofi Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 50. Mylan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 51. Apotex Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 52. Glemark Generics Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 53. Covis Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 54. Sun Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 55. Lunan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2020-2025)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
